The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Cognitive decline in Parkinson disease
Open accessAbstract
Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD). In recent years, research has focused on the pre-dementia stages of cognitive impairment in PD, including mild cognitive impairment (MCI). Several longitudinal studies have shown that MCI is a harbinger of dementia in PD, although the course is variable, and stabilization of cognition - or even reversal to normal cognition - is not uncommon. In addition to limbic and cortical spread of Lewy pathology, several other mechanisms are likely to contribute to cognitive decline in PD, and a variety of biomarker studies, some using novel structural and functional imaging techniques, have documented in vivo brain changes associated with cognitive impairment. The evidence consistently suggests that low cerebrospinal fluid levels of amyloid-β 42, a marker of comorbid Alzheimer disease (AD), predict future cognitive decline and dementia in PD. Emerging genetic evidence indicates that in addition to the APOE*ε4 allele (an established risk factor for AD), GBA mutations and SCNA mutations and triplications are associated with cognitive decline in PD, whereas the findings are mixed for MAPT polymorphisms. Cognitive enhancing medications have some effect in PD dementia, but no convincing evidence that progression from MCI to dementia can be delayed or prevented is available, although cognitive training has shown promising results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover there are several candidate genetic risk factors that overlap for AD and PD, most notably APOE and MAPT [127].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Self-citationLitvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609
Self-citationThe Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., ADENA, M. A., Halliday, G. M., & Morris, J. G. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,346
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Self-citationMultimodal classification of Alzheimer's disease and mild cognitive impairment
Zhang, D., Wang, Y., Zhou, L., Yuan, H., & Shen, D. G. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.008 · Cited by 1,340
Rivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., Deyn, P. P. D., Durif, F., Kulisevsky, J., van Laar, T., Lees, A. J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,219
Self-citationThe distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
Williams‐Gray, C. H., Evans, J., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., Brayne, C., Kolachana, B. S., Weinberger, D. R., Sawcer, S. J., et al. (2009) · Brain · doi:10.1093/brain/awp245 · Cited by 1,017
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
Irwin, D. J., Lee, V. M. ‐., & Trojanowski, J. Q. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3549 · Cited by 914
Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications
Farrer, M. J., Kachergus, J. M., Forno, L. S., Lincoln, S., Wang, D., Hulihan, M., Maraganore, D. M., Gwinn, K. A., Wszołek, Z. K., Dickson, D. W., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10846 · Cited by 711
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort
Williams‐Gray, C. H., Mason, S., Evans, J., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305277 · Cited by 683
Schulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
Compta, Y., Parkkinen, L., O’Sullivan, S. S., Vandrovcová, J., Holton, J. L., Collins, C., Lashley, T., Kallis, C., Williams, D. R., de Silva, R., et al. (2011) · Brain · doi:10.1093/brain/awr031 · Cited by 607
Cognitive Impairment in Parkinson’s Disease: The Dual Syndrome Hypothesis
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2012) · Neurodegenerative Diseases · doi:10.1159/000341998 · Cited by 574
Bohnen, N. I., Kaufer, D., Ivanco, L. S., Lopresti, B. J., Koeppe, R. A., Davis, J. G., Mathis, C. A., Moore, R. Y., & DeKosky, S. T. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1745 · Cited by 561
Minoshima, S., Foster, N. L., Sima, A. A. F., Frey, K. A., Albin, R. L., & Kuhl, D. E. (2001) · Annals of Neurology · doi:10.1002/ana.1133 · Cited by 560
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
Svenningsson, P., Westman, E., Ballard, C. G., & Aarsland, D. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70152-7 · Cited by 517
Self-citationAarsland, D., Ballard, C. G., Walker, Z., Boström, F., Alves, G. W., Kossakowski, K., Leroi, I., Pozo-Rodriguez, F., Minthon, L., & Londos, E. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70146-2 · Cited by 464
Self-citationGenetic screening for a single common LRRK2 mutation in familial Parkinson's disease
Nichols, W. C., Pankratz, N., Hernandez, D., Paisán-Ruíz, C., Jain, S., Halter, C. A., Michaels, V. E., Reed, T., Rudolph, A., Shults, C. W., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17828-3 · Cited by 457
Emre, M., Tsolaki, M., Bonuccelli, U., Destée, A., TOLOSA, E. S., Kutzelnigg, A., Ceballos-Baumann, A., Zdravkovic, S., Bladström, A., & Jones, R. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70194-0 · Cited by 451
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445
Edison, P., Rowe, C. C., Rinne, J. O., Ng, S., Ahmed, I., Kemppainen, N. M., Villemagne, V. L., O'Keefe, G. J., Någren, K., Chaudhuri, К. R., et al. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.127878 · Cited by 428
Survival and dementia in GBA ‐associated Parkinson's disease: T he mutation matters
Cilia, R., Tùnesi, S., Marotta, G., Cereda, E., Siri, C., Tesei, S., Zecchinelli, A., Canesi, M., Mariani, C. B., Meucci, N., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24777 · Cited by 415
Changes in network activity with the progression of Parkinson's disease
Huang, C. C., Tang, C., Feigin, A., LESSER, M. L., Ma, Y., Pourfar, M., DHAWAN, V. M., & Eidelberg, D. (2007) · Brain · doi:10.1093/brain/awm086 · Cited by 406
Hilker, R., Thomas, A. V., Klein, J. C., Weisenbach, S., Kalbe, E., Burghaus, L., Jacobs, A. H., Herholz, K., & Wd, H. (2005) · Neurology · doi:10.1212/01.wnl.0000191154.78131.f6 · Cited by 387
The neurobiological basis of cognitive impairment in Parkinson's disease
Halliday, G. M., Leverenz, J. B., Schneider, J. S., & Adler, C. H. (2014) · Movement Disorders · doi:10.1002/mds.25857 · Cited by 386
CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
Siderowf, A. D., Xie, S. X., Hurtig, H. I., Weintraub, D. A., Duda, J. E., Chen‐Plotkin, A. S., Shaw, L. M. J., Deerlin, V. M. V., Trojanowski, J. Q., & Clark, C. N. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39a78 · Cited by 386
Self-citationPredictors of dementia in Parkinson disease
Anang, J. B. M., Gagnon, J., Bertrand, J., Romenets, S. R., Latreille, V., Panisset, M., Montplaisir, J. Y., & Postuma, R. B. (2014) · Neurology · doi:10.1212/wnl.0000000000000842 · Cited by 379
Non motor subtypes and Parkinson's disease
Sauerbier, A., Jenner, P. G., Todorova, A., & Chaudhuri, К. R. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.027 · Cited by 377
Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET
Shimada, H., Hirano, S., Shinotoh, H., Aotsuka, A., Sato, K., Tanaka, N., Ota, T., Asahina, M., Fukushi, K., Kuwabara, S., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181ab2b58 · Cited by 371
Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo
Klein, J. C., Eggers, C., Kalbe, E., Weisenbach, S., Hohmann, C., Vollmar, S., Baudrexel, S., Diederich, N. J., Heiß, W.-D., & Hilker, R. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d55f61 · Cited by 361
Differences in neuropathologic characteristics across the Lewy body dementia spectrum
Ballard, C., Ziabreva, I., Perry, R., Larsen, J. P., O'Brien, J., McKeith, I., Perry, E., & Aarsland, D. (2006) · Neurology · doi:10.1212/01.wnl.0000249130.63615.cc · Cited by 335
Self-citationNonmotor features of Parkinson's disease subtypes
Marras, C., & Chaudhuri, К. R. (2016) · Movement Disorders · doi:10.1002/mds.26510 · Cited by 327
Cognitive training in Parkinson disease
Leung, I. H. K., Walton, C. C., Hallock, H., Lewis, S. J. G., Valenzuela, M., & Lampit, A. (2015) · Neurology · doi:10.1212/wnl.0000000000002145 · Cited by 318
Prognosis of Mild Cognitive Impairment in Early Parkinson Disease: The Norwegian ParkWest Study
Pedersen, K. F., Larsen, J. P., Tysnes, O.-B., & Alves, G. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2110 · Cited by 315
Caffeine for treatment of Parkinson disease
Postuma, R. B., Lang, A. E., Munhoz, R. P., Charland, K., Pelletier, A., Moscovich, M., Filla, L., Zanatta, D., Romenets, S. R., Altman, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318263570d · Cited by 311
Winder‐Rhodes, S., Evans, J., Ban, M., Mason, S., Williams‐Gray, C. H., Foltynie, T., Durán, R., Mencacci, N. E., Sawcer, S. J., & Barker, R. A. (2013) · Brain · doi:10.1093/brain/aws318 · Cited by 292
Parkinson's disease, insulin resistance and novel agents of neuroprotection
Avilés-Olmos, I., Limousin, P. D., Lees, A. J., & Foltynie, T. (2012) · Brain · doi:10.1093/brain/aws009 · Cited by 291
Lindqvist, D., Hall, S., Surova, Y., Nielsen, H. M., Janelidze, S., Brundin, L., & Hansson, O. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2013.07.007 · Cited by 278
Wang, H.-F., Yu, J., Tang, S., Jiang, T., Tan, C.-C., Meng, X.-F., Wang, C., Tan, M., & Tan, L. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307659 · Cited by 275
Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease
Goris, A., Williams‐Gray, C. H., Clark, G. R., Foltynie, T., Lewis, S. J. G., Brown, J., Ban, M., Spillantini, M. G., Compston, A., Burn, D. J., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21192 · Cited by 273
Cognitive performance of GBA mutation carriers with early-onset PD
Alcalay, R. N., Caccappolo, E., Mejia‐Santana, H., Tang, M. X., Rosado, L., Reilly, M. O., Ruiz, D., Ross, B., Verbitsky, M., Kisselev, S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318253d54b · Cited by 268
Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's
Liu, G., Boot, B. P., Locascio, J. J., Jansen, I. E., Winder‐Rhodes, S., Eberly, S. W., Elbaz, A., Brice, A., Ravina, B. M., van Hilten, J. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24781 · Cited by 266
Neuroimaging in Parkinson disease: from research setting to clinical practice
Politis, M. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.205 · Cited by 264
Self-citationDeep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s dementia
Kuhn, J., Hardenacke, K., Lenartz, D., Gruendler, T. O. J., Ullsperger, M., Bartsch, C., Mai, J. K., Zilles, K., Bauer, A., Matusch, A., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.32 · Cited by 262
Mak, E., Su, L., Williams, G. B., Firbank, M., Lawson, R. A., Yarnall, A. J., Duncan, G. W., Owen, A. M., Khoo, T. K., Brooks, D. J., et al. (2015) · Brain · doi:10.1093/brain/awv211 · Cited by 261
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Colcher, A., Horn, S. S., Nazem, S., Ten Have, T. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd79 · Cited by 255
Self-citationEhrt, U., Broich, K., Larsen, J. P., Ballard, C., & Aarsland, D. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.186239 · Cited by 254
Self-citationMartínez‐Martín, P., Reddy, P., Katzenschlager, R., Antonini, A., Todorova, A., Odin, P., Henriksen, T., Martin, A., Calandrella, D., Rizos, A., et al. (2014) · Movement Disorders · doi:10.1002/mds.26067 · Cited by 252
Longitudinal study of normal cognition in Parkinson disease
Pigott, K., Rick, J., Xie, S. X., Hurtig, H., Chen-Plotkin, A., Duda, J. E., Morley, J. F., Chahine, L. M., Dahodwala, N., Akhtar, R. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002001 · Cited by 251
Self-citationCSF biomarkers and clinical progression of Parkinson disease
Hall, S., Surova, Y., Öhrfelt, A., Zetterberg, H., Lindqvist, D., & Hansson, O. (2014) · Neurology · doi:10.1212/wnl.0000000000001098 · Cited by 236
Increased CSF neurogranin concentration is specific to Alzheimer disease
Wellington, H., Paterson, R. W., Portelius, E., Törnqvist, U., Magdalinou, N., Fox, N. C., Blennow, K., Schott, J. M., & Zetterberg, H. (2016) · Neurology · doi:10.1212/wnl.0000000000002423 · Cited by 232
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases
Gomperts, S. N., Locascio, J. J., Makaretz, S. J., Schultz, A. P., Caso, C., Vasdev, N., Sperling, R. A., Growdon, J. H., Dickerson, B. C., & Johnson, K. A. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3338 · Cited by 228
Hanganu, A., Bedetti, C., Degroot, C., Mejia‐Constain, B., Lafontaine, A., Soland, V., Chouinard, S., Bruneau, M., Mellah, S., Belleville, S., et al. (2014) · Brain · doi:10.1093/brain/awu036 · Cited by 223
Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt–PCP–JNK pathway
Killick, R., Ribe, E. M., Al-Shawi, R., Malik, B., Hooper, C., Fernandes, C., Dobson, R., Nolan, P. M., Lourdusamy, A., Furney, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2012.163 · Cited by 222
Quantitative EEG as a predictive biomarker for Parkinson disease dementia
Klassen, B. T., Hentz, J. G., Shill, H. A., Driver‐Dunckley, E. D., Evidente, V. G. H., Sabbagh, M. N., Adler, C. H., & Caviness, J. N. (2011) · Neurology · doi:10.1212/wnl.0b013e318224af8d · Cited by 215
Hansson, O., Hall, S., Öhrfelt, A., Zetterberg, H., Blennow, K., Minthon, L., Nägga, K., Londos, E., Varghese, S., Majbour, N. K., et al. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt255 · Cited by 214
Fan, Z., Aman, Y., Ahmed, I., Chetelat, G., Landeau, B., Ray Chaudhuri, K., Brooks, D. J., & Edison, P. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.016 · Cited by 212
GBA Variants are associated with a distinct pattern of cognitive deficits in P arkinson's disease
Mata, I. F., Leverenz, J. B., Weintraub, D. A., Trojanowski, J. Q., Chen‐Plotkin, A. S., Deerlin, V. M. V., Ritz, B. R., Rausch, R., Factor, S. A., Wood‐Siverio, C., et al. (2015) · Movement Disorders · doi:10.1002/mds.26359 · Cited by 210
Self-citationAmyloid deposition in Parkinson's disease and cognitive impairment: A systematic review
Petrou, M., Dwamena, B. A., Foerster, B. R., MacEachern, M. P., Bohnen, N. I., Müller, M. L., Albin, R. L., & Frey, K. A. (2015) · Movement Disorders · doi:10.1002/mds.26191 · Cited by 208
Review: Parkinson's disease: from synaptic loss to connectome dysfunction
Bellucci, A., Mercuri, N. B., Venneri, A., Faustini, G., Longhena, F., Pizzi, M., Missale, C., & Spano, P. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12297 · Cited by 208
APOE,MAPT, andSNCAGenes and Cognitive Performance in Parkinson Disease
Mata, I. F., Leverenz, J. B., Weintraub, D. A., Trojanowski, J. Q., Hurtig, H. I., Deerlin, V. M. V., Ritz, B. R., Rausch, R., Rhodes, S. L., Factor, S. A., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1455 · Cited by 203
Self-citationDonepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study
Dubois, B., Tolosa, E., Katzenschlager, R., Emre, M., Lees, A. J., Schumann, G., Pourcher, E., Gray, J., Thomas, G., Swartz, J., et al. (2012) · Movement Disorders · doi:10.1002/mds.25098 · Cited by 202
Evolution of mild cognitive impairment in Parkinson disease
Broeders, M., de Bie, R. M. A., Velseboer, D. C., Speelman, J. D., Muslimović, D., & Schmand, B. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31829c5c86 · Cited by 201
Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease
Bäckström, D. C., Domellöf, M. E., Linder, J., Olsson, B., Öhrfelt, A., Trupp, M., Zetterberg, H., Blennow, K., & Forsgren, L. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1449 · Cited by 200
Andreassen, O. A., Harbo, H. F., Wang, Y., Thompson, W. K., Schork, A. J., Mattingsdal, M., Zuber, V., Bettella, F., Ripke, S., Kelsoe, J. R., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.195 · Cited by 200
Regional Multiple Pathology Scores Are Associated with Cognitive Decline in L ewy Body Dementias
Howlett, D. R., Whitfield, D., Johnson, M. A., Attems, J., O'Brien, J. T., Aarsland, D., Lai, M. K. P., Lee, J. H., Chen, C., Ballard, C. G., et al. (2014) · Brain Pathology · doi:10.1111/bpa.12182 · Cited by 199
Self-citationClinical features of LRRK2‐associated Parkinson's disease in central Norway
Aasly, J. O., Toft, M., Mata, I. F., Kachergus, J. M., Hulihan, M., White, L. R., & Farrer, M. J. (2005) · Annals of Neurology · doi:10.1002/ana.20456 · Cited by 195
Cortical thinning is associated with disease stages and dementia in Parkinson's disease
Zarei, M., Ibarretxe‐Bilbao, N., Compta, Y., Hough, M., Junqué, C., Bargalló, N., Tolosa, E., & Martí, M. J. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304126 · Cited by 192
Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia
Gomperts, S. N., Locascio, J. J., Rentz, D. M., Santarlasci, A., Marquié, M., Johnson, K. A., & Growdon, J. H. (2012) · Neurology · doi:10.1212/wnl.0b013e31827b1a07 · Cited by 189
Ibarretxe‐Bilbao, N., Junqué, C., TOLOSA, E. S., Martı́, M. J., Valldeoriola, F., Bargalló, N., & Zarei, M. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06892.x · Cited by 187
Exercise improves cognition in Parkinson's disease: The PRET‐PD randomized, clinical trial
David, F. J., Robichaud, J. A., Leurgans, S. E., Poon, C., Kohrt, W. M., Goldman, J. G., Comella, C. L., Vaillancourt, D. E., & Corcos, D. M. (2015) · Movement Disorders · doi:10.1002/mds.26291 · Cited by 186
Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia
Bohnen, N. I., Müller, M. L. T. M., Kotagal, V., Koeppe, R. A., Kilbourn, M. R., Gilman, S., Albin, R. L., & Frey, K. A. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.60 · Cited by 186
Role of Dopamine in Learning and Memory
Kulisevsky, J. (2000) · Drugs & Aging · doi:10.2165/00002512-200016050-00006 · Cited by 183
Williams‐Gray, C. H., Hampshire, A., Robbins, T. W., Owen, A. M., & Barker, R. A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0774-07.2007 · Cited by 181
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., Carlo, C. D., Giannandrea, D., Salvadori, N., Lisetti, V., Tambasco, N., Rossi, A., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00053 · Cited by 180
Agosta, F., Canu, E., Stefanova, E. D., Sarro, L., Tomić, A., Marković, V., Comı, G., Kostić, V., & Filippi, M. (2013) · Human Brain Mapping · doi:10.1002/hbm.22302 · Cited by 174
Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia
Bereczki, E., Francis, P. T., Howlett, D., Pereira, J. B., Höglund, K., Bogstedt, A., Cedazo‐Minguez, A., Baek, J., Hortobágyi, T., Attems, J., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.04.005 · Cited by 167
Self-citationFunctional connectivity and cognitive decline over 3 years in Parkinson disease
Dubbelink, K. T. E. O., Schoonheim, M. M., Deijen, J. B., Twisk, J. W. R., Barkhof, F., & Berendse, H. W. (2014) · Neurology · doi:10.1212/wnl.0000000000001020 · Cited by 165
Attentional control in Parkinson's disease is dependent on COMT val158met genotype
Williams‐Gray, C. H., Hampshire, A., Barker, R., & Owen, A. M. (2008) · Brain · doi:10.1093/brain/awm313 · Cited by 165
L ongitudinal M easurements of C erebrospinal F luid B iomarkers in P arkinson's D isease
Hall, S., Surova, Y., Öhrfelt, A., Study, T. S. B., Blennow, K., Zetterberg, H., & Hansson, O. (2016) · Movement Disorders · doi:10.1002/mds.26578 · Cited by 165
Gonzalez-Redondo, R., García‐García, D., Clavero, P., Gasca‐Salas, C., de Eulate, M. R. G., Zubieta, J. L., Arbizu, J., Obeso, J. A., & Rodríguez‐Oroz, M. (2014) · Brain · doi:10.1093/brain/awu159 · Cited by 163
Ito, K., Nagano‐Saito, A., Kato, T., Arahata, Y., Nakamura, A., Kawasumi, Y., Hatano, K., Abe, Y., Yamada, T., Kachi, T., et al. (2002) · Brain · doi:10.1093/brain/awf134 · Cited by 163
Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study
Compta, Y., Pereira, J. B., Ríos, J., Ibarretxe‐Bilbao, N., Junqué, C., Bargalló, N., Cámara, A., Buongiorno, M., Fernández, M., Pont‐Sunyer, C., et al. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.03.009 · Cited by 163
Borght, T. V., Minoshima, S., Giordani, B., Foster, N. L., Frey, K. A., Berent, S., Albin, R. L., Koeppe, R. A., & Kuhl, D. E. (1997) · PubMed · Cited by 160
Cognitive function in the early phase of Parkinson's disease, a five-year follow-up
Domellöf, M., Ekman, U., Forsgren, L., & Elgh, E. (2015) · Acta Neurologica Scandinavica · doi:10.1111/ane.12375 · Cited by 160
CSF Aβ 42 predicts early-onset dementia in Parkinson disease
Alves, G. W., Lange, J., Blennow, K., Zetterberg, H., Andréasson, U., Førland, M. G. G., Tysnes, O., Larsen, J. O., & Pedersen, K. F. (2014) · Neurology · doi:10.1212/wnl.0000000000000425 · Cited by 158
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease
Williams‐Gray, C. H., Goris, A., Saiki, M., Foltynie, T., Compston, D. A. S., Sawcer, S. J., & Barker, R. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0119-8 · Cited by 157
Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course
Setó‐Salvia, N., Pagonabarraga, J., Houlden, H., Pascual‐Sedano, B., Dols‐Icardo, O., Tucci, A., Paisán‐Ruiz, C., Campolongo, A., Antón‐Aguirre, S., Martín, I. R., et al. (2011) · Movement Disorders · doi:10.1002/mds.24045 · Cited by 156
Apomorphine treatment in Alzheimer mice promoting amyloid‐β degradation
Himeno, E., Ohyagi, Y., Ma, L., Nakamura, N., Miyoshi, K., Sakae, N., Motomura, K., Soejima, N., Yamasaki, R., Hashimoto, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22319 · Cited by 155
Gray and white matter imaging: A biomarker for cognitive impairment in early P arkinson's disease?
Duncan, G. W., Firbank, M., Yarnall, A. J., Khoo, T. K., Brooks, D. J., Barker, R. A., Burn, D. J., & O'Brien, J. T. (2015) · Movement Disorders · doi:10.1002/mds.26312 · Cited by 154
Lee, J. E., Cho, K. H., Song, S. K., Kim, H. J., Lee, H. S., Sohn, Y. H., & Lee, P. H. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305062 · Cited by 154
Genetic influences on cognitive decline in Parkinson's disease
Morley, J. F., Xie, S. X., Hurtig, H. I., Stern, M. B., Colcher, A., Horn, S. S., Dahodwala, N. A., Duda, J. E., Weintraub, D. A., Chen‐Plotkin, A. S., et al. (2012) · Movement Disorders · doi:10.1002/mds.24946 · Cited by 152
Self-citationMonitoring of 30 marker candidates in early Parkinson disease as progression markers
Mollenhauer, B., Zimmermann, J., Sixel‐Döring, F., Focke, N. K., Wicke, T., Ebentheuer, J., Schaumburg, M., Lang, E., Trautmann, E., Zetterberg, H., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002651 · Cited by 151
Targeting impulsivity in Parkinson’s disease using atomoxetine
Kehagia, A. A., Housden, C. R., Regenthal, R., Barker, R. A., Müller, U., Rowe, J. B., Sahakian, B. J., & Robbins, T. W. (2014) · Brain · doi:10.1093/brain/awu117 · Cited by 150
Chahine, L. M., Qiang, J., Ashbridge, E., Minger, J., Yearout, D., Horn, S., Colcher, A., Hurtig, H. I., Lee, V. M.-Y., Van Deerlin, V. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1274 · Cited by 150
Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinson’s Disease
Pagonabarraga, J., Corcuera‐Solano, I., Vives‐Gilabert, Y., Llebaria, G., García‐Sánchez, C., Pascual‐Sedano, B., Delfino, M., Kulisevsky, J., & Gómez‐Ansón, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054980 · Cited by 149
Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study
Santangelo, G., Vitale, C., Picillo, M., Moccia, M., Cuoco, S., Longo, K., Pezzella, D., di Grazia, A., Erro, R., Pellecchia, M. T., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.08.024 · Cited by 149
The nucleus basalis of Meynert: A new target for deep brain stimulation in dementia?
Gratwicke, J., Kahan, J., Zrinzo, L. U., Hariz, M. I., Limousin, P. D., Foltynie, T., & Jahanshahi, M. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.09.003 · Cited by 148
Nombela, C., Rowe, J. B., Winder‐Rhodes, S., Hampshire, A., Owen, A. M., Breen, D. P., Duncan, G. W., Khoo, T. K., Yarnall, A. J., Firbank, M., et al. (2014) · Brain · doi:10.1093/brain/awu201 · Cited by 146
Dementia Risk in Parkinson Disease
Setó‐Salvia, N., Clarimón, J., Pagonabarraga, J., Pascual‐Sedano, B., Campolongo, A., Combarros, O., Mateo, J. I., Regaña, D., Martínez-Corral, M., Marquié, M., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.17 · Cited by 145
Whitfield, D., Vallortigara, J., Alghamdi, A., Howlett, D. R., Hortobágyi, T., Johnson, M., Attems, J., Newhouse, S., Ballard, C. G., Thomas, A. J., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.015 · Cited by 144
Self-citationStewart, T., Liu, C., Ginghină, C., Cain, K. C., Auinger, P., Cholerton, B., Shi, M. Y., & Zhang, J. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.12.007 · Cited by 144
Reynolds, G., Otto, M. W., Ellis, T. D., & Cronin‐Golomb, A. (2015) · Movement Disorders · doi:10.1002/mds.26484 · Cited by 144
Yong, S. W., Yoon, J., An, Y., & Lee, P. H. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01977.x · Cited by 142
Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus
Desikan, R. S., Schork, A. J., Wang, Y., Witoelar, A., Sharma, M., McEvoy, L. K., Holland, D., Brewer, J. B., Chen, C., Thompson, W. K., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.6 · Cited by 142
Self-citation[11C]PIB binding in Parkinson's disease dementia
Maetzler, W., Reimold, M., Liepelt, I., Solbach, C., Leyhe, T., Schweitzer, K. J., Eschweiler, G. W., Mittelbronn, M. G. A., Gaenslen, A., Uebele, M., et al. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.072 · Cited by 137
Valera, E., Spencer, B. J., & Masliah, E. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0397-z · Cited by 135
Hippocampal abnormalities and memory deficits in Parkinson disease
Carlesimo, G. A., Piras, F., Assogna, F., Pontieri, F. E., Caltagirone, C., & Spalletta, G. (2012) · Neurology · doi:10.1212/wnl.0b013e318259e1c5 · Cited by 129
Motor and nonmotor heterogeneity of LRRK2 ‐related and idiopathic Parkinson's disease
Marras, C., Alcalay, R. N., Caspell‐Garcia, C., Coffey, C. S., Chan, P., Duda, J. E., Facheris, M., Fernández‐Santiago, R., Ruiz‐Martínez, J., Mestre, T., et al. (2016) · Movement Disorders · doi:10.1002/mds.26614 · Cited by 128
Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study
Mamikonyan, E., Xie, S. X., Melvin, E., & Weintraub, D. A. (2015) · Movement Disorders · doi:10.1002/mds.26236 · Cited by 122
Self-citationPlanning ability in Parkinson's disease is influenced by the COMT val 158 met polymorphism
Foltynie, T., Goldberg, T. E., Lewis, S. J. G., Blackwell, A. D., Kolachana, B. S., Weinberger, D. R., Robbins, T. W., & Barker, R. A. (2004) · Movement Disorders · doi:10.1002/mds.20118 · Cited by 122
Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease
Pereira, J. B., Aarsland, D., Ginestet, C. E., Lebedev, A. V., Wahlund, L., Simmons, A., Volpe, G., & Westman, E. (2015) · Human Brain Mapping · doi:10.1002/hbm.22822 · Cited by 121
Self-citationImaging of microglia in patients with neurodegenerative disorders
Politis, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00096 · Cited by 111
Self-citationFirst appraisal of brain pathology owing to A30P mutant alpha‐synuclein
Seidel, K., Schöls, L. J., Nuber, S., Petrasch‐Parwez, E., Gierga, K., Wszołek, Z. K., Dickson, D. W., Gai, W., Bornemann, A., Rieß, O., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21966 · Cited by 110
Öhrfelt, A., Zetterberg, H., Andersson, K., Persson, R., Secic, D., Brinkmalm, G., Wallin, A., Mulugeta, E., Francis, P. T., Vanmechelen, E., et al. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0527-x · Cited by 109
Self-citationChahine, L. M., Weintraub, D. A., Hawkins, K. A., Siderowf, A. D., Eberly, S. W., Oakes, D., Seibyl, J. P., Stern, M. B., MAREK, K. L., Jennings, D. L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26373 · Cited by 108
Self-citationGoldwurm, S., Zini, M., Fonzo, A. D., Gaspari, D. D., Siri, C., Simons, E. J., van Doeselaar, M., Tesei, S., Antonini, A., Canesi, M., et al. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.04.001 · Cited by 108
Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson’s disease patients
Paul, G., Zachrisson, O., Varrone, A., Almqvist, P. M., Jerling, M., Lind, G., Rehncrona, S., Linderoth, B., Bjartmarz, H., Shafer, L. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79635 · Cited by 107
Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease
Oeda, T., Umemura, A., Mori, Y., Tomita, S., Kohsaka, M., Park, K., Inoue, K., Fujimura, H., Hasegawa, H., Sugiyama, H., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.027 · Cited by 106
A large study reveals no association between APOE and Parkinson's disease
Federoff, M., Jimenez‐Rolando, B., Nalls, M. A., & Singleton, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.02.002 · Cited by 106
A Swedish family with de novo α-synuclein A53T mutation: Evidence for early cortical dysfunction
Puschmann, A., Ross, O. A., Vilariño‐Güell, C., Lincoln, S., Kachergus, J. M., Cobb, S. A., Lindquist, S. G., Nielsen, J. E., Wszołek, Z. K., Farrer, M. J., et al. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.06.007 · Cited by 105
Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease
Kandiah, N., Zainal, N. H., Narasimhalu, K., Chander, R. J., Ng, A. Y. T., Mak, E., Au, W. L., Sitoh, Y. Y., Nadkarni, N. V., & Tan, L. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.08.024 · Cited by 105
CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease
Terrelonge, M., Marder, K. S., Weintraub, D. A., & Alcalay, R. N. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0647-x · Cited by 102
Self-citationAβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia
Petrou, M., Bohnen, N. I., Müller, M. L. T. M., Koeppe, R. A., Albin, R. L., & Frey, K. A. (2012) · Neurology · doi:10.1212/wnl.0b013e3182698d4a · Cited by 102
Cholinergic imaging in dementia spectrum disorders
Roy, R., Niccolini, F., Pagano, G., & Politis, M. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3349-x · Cited by 101
Self-citationBiomarkers of cognitive decline in Parkinson's disease
Lin, C., & Wu, R. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.02.010 · Cited by 100
Event-related potentials and cognition in Parkinson’s disease: An integrative review
Seer, C., Lange, F., Georgiev, D., Jahanshahi, M., & Kopp, B. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.08.003 · Cited by 100
Chen, B., Fan, G. G., Liu, H., & Wang, S. (2015) · European Journal of Radiology · doi:10.1016/j.ejrad.2015.04.014 · Cited by 98
Simonsen, A. H., Kuiperij, H. B., El‐Agnaf, O. M. A., Engelborghs, S., Herukka, S., Parnetti, L., Rektorová, I., Vanmechelen, E., Kapaki, E. N., Verbeek, M. M., et al. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.14.105 · Cited by 97
Belarbi, S., Hecham, N., Lesage, S., Kediha, M. I., Smail, N., Benhassine, T., Ysmail-Dahlouk, F., Lohman, E., Benhabyles, B., Hamadouche, T., et al. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.09.003 · Cited by 94
α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease
Guella, I., Evans, D. M., Szu‐Tu, C., Nosova, E., Bortnick, S., SNCA Cognition Study Group, Goldman, J. G., Dalrymple‐Alford, J. C., Geurtsen, G. J., Litvan, I., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24664 · Cited by 94
Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative
Ffytche, D. H., Pereira, J. B., Ballard, C. G., Chaudhuri, К. R., Weintraub, D. A., & Aarsland, D. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314832 · Cited by 94
Self-citationLongitudinal EEG Changes Correlate with Cognitive Measure Deterioration in Parkinson's Disease
Caviness, J. N., Hentz, J. G., Belden, C. M., Shill, H. A., Driver‐Dunckley, E. D., Sabbagh, M. N., Powell, J. J., & Adler, C. H. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-140480 · Cited by 94
Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency
Gatt, A. P., Duncan, O. F., Attems, J., Francis, P. T., Ballard, C. G., & Bateman, J. E. (2016) · Movement Disorders · doi:10.1002/mds.26513 · Cited by 92
Self-citationRektorová, I., Krajčovičová, L., Mareček, R., & Mikl, M. (2012) · Neurodegenerative Diseases · doi:10.1159/000334765 · Cited by 90
Borroni, B., Premi, E., Formenti, A., Turrone, R., Alberici, A., Cottini, E., Rizzetti, M. C., Gasparotti, R., & Padovani, A. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.06.013 · Cited by 90
Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism
Pappatà, S., Santangelo, G., Aarsland, D., Vicidomini, C., Longo, K., Brønnick, K., Amboni, M., Erro, R., Vitale, C., Caprio, M. G., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182315259 · Cited by 89
Self-citationvan Dijk, K. D., Bidinosti, M., Weiss, A., Raijmakers, P., Berendse, H. W., & van de Berg, W. D. J. (2014) · European Journal of Neurology · doi:10.1111/ene.12176 · Cited by 88
Do Subjective Memory Complaints Herald the Onset of Mild Cognitive Impairment in Parkinson Disease?
Erro, R., Santangelo, G., Barone, P., Picillo, M., Amboni, M., Longo, K., Giordano, F., Moccia, M., Allocca, R., Pellecchia, M. T., et al. (2014) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988714532015 · Cited by 86
Fonseca, L. C., Tedrus, G. M. A. S., Carvas, P. N., & Machado, E. C. F. A. (2013) · Clinical Neurophysiology · doi:10.1016/j.clinph.2013.05.001 · Cited by 85
COPPADIS Study Group, Santos‐García, D., Mir, P., Cubo, E., Vela, L., Rodríguez‐Oroz, M., Martı́, M. J., Arbelo, J. M., Infante, J., Kulisevsky, J., et al. (2016) · BMC Neurology · doi:10.1186/s12883-016-0548-9 · Cited by 83
Different PD-MCI criteria and risk of dementia in Parkinson’s disease: 4-year longitudinal study
Horne, K., Myall, D. J., Livingston, L., Melzer, T. R., Pitcher, T. L., MacAskill, M. R., Geurtsen, G. J., Anderson, T., & Dalrymple‐Alford, J. C. (2016) · npj Parkinson s Disease · doi:10.1038/npjparkd.2015.27 · Cited by 83
Cognitive profile of LRRK2‐related Parkinson's disease
Srivatsal, S. R., Cholerton, B., Leverenz, J. B., Wszołek, Z. K., Uitti, R. J., Dickson, D. W., Weintraub, D. A., Trojanowski, J. Q., Deerlin, V. M. V., Quinn, J. F., et al. (2015) · Movement Disorders · doi:10.1002/mds.26161 · Cited by 82
Self-citationThalamic cholinergic innervation is spared in Alzheimer disease compared to parkinsonian disorders
Kotagal, V., Müller, M. L. T. M., Kaufer, D., Koeppe, R. A., & Bohnen, N. I. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.02.083 · Cited by 82
Grey Matter Changes in Cognitively Impaired Parkinson's Disease Patients
Rektorová, I., Biundo, R., Mareček, R., Weis, L., Aarsland, D., & Antonini, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085595 · Cited by 81
Self-citationSeibert, T. M., Murphy, E. A., Kaestner, E. J., & Brewer, J. B. (2012) · Radiology · doi:10.1148/radiol.12111280 · Cited by 80
APOE , MAPT , and COMT and Parkinson’s Disease Susceptibility and Cognitive Symptom Progression
Paul, K. C., Rausch, R., Creek, M. M., Sinsheimer, J. S., Bronstein, J. M., Bordelon, Y. M., & Ritz, B. R. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-150762 · Cited by 79
Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease
Stav, A. L., Aarsland, D., Johansen, K. K., Hessen, E., Auning, E., & Fladby, T. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.04.027 · Cited by 76
Self-citationLeverenz, J. B., Watson, G. S., Shofer, J., Zabetian, C. P., Zhang, J., & Montine, T. J. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.10.003 · Cited by 75
Heron, C. J. L., Wright, S. L., Melzer, T. R., Myall, D. J., MacAskill, M. R., Livingston, L., Keenan, R. J., Watts, R., Dalrymple‐Alford, J. C., & Anderson, T. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.40 · Cited by 74
Mollenhauer, B., Parnetti, L., Rektorová, I., Kramberger, M. G., Pikkarainen, M., Schulz‐Schaeffer, W., Aarsland, D., Svenningsson, P., Farotti, L., Verbeek, M. M., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13390 · Cited by 73
Self-citationKurz, M. W., Schlitter, A. M., Klenk, Y., Mueller, T., Larsen, J. P., Aarsland, D., & Dekomien, G. (2007) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988706297737 · Cited by 73
Self-citationSynaptic proteins in CSF relate to Parkinson’s disease stage markers
Bereczki, E., Bogstedt, A., Höglund, K., Tsitsi, P., Brodin, L., Ballard, C., Svenningsson, P., & Aarsland, D. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0008-2 · Cited by 72
Self-citationYe, Z., Rae, C. L., Nombela, C., Ham, T. E., Rittman, T., Jones, P. S., Rodríguez, P. V., Coyle-Gilchrist, I. T. S., Regenthal, R., Altena, E., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23087 · Cited by 71
Mitochondrial retrograde signaling regulates neuronal function
Cagin, U., Duncan, O. F., Gatt, A. P., Dionne, M., Sweeney, S. T., & Bateman, J. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505036112 · Cited by 66
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo‐controlled trial
Weintraub, D. A., Hauser, R. A., Elm, J. J., Pagán, F., Davis, M. D., Choudhry, A., & for the MODERATO Investigators (2016) · Movement Disorders · doi:10.1002/mds.26617 · Cited by 66
Self-citationZhou, B., Wen, M., Yu, W., Zhang, C., & Jiao, L. (2015) · Parkinson s Disease · doi:10.1155/2015/567386 · Cited by 65
CSF proteins and resting-state functional connectivity in Parkinson disease
Campbell, M. C., Koller, J. M., Snyder, A. Z., Buddhala, C., Kotzbauer, P. T., & Perlmutter, J. S. (2015) · Neurology · doi:10.1212/wnl.0000000000001681 · Cited by 65
Quantitative EEG Analysis of Executive Dysfunction in Parkinson Disease
Kamei, S., Morita, A., Serizawa, K., Mizutani, T., & Hirayanagi, K. (2010) · Journal of Clinical Neurophysiology · doi:10.1097/wnp.0b013e3181dd4fdb · Cited by 64
The Genetic Basis of Cognitive Impairment and Dementia in Parkinson’s Disease
Collins, L., & Williams‐Gray, C. H. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00089 · Cited by 64
Positron emission tomography neuroimaging in Parkinson's disease.
Loane, C., & Politis, M. (2011) · PubMed · Cited by 63
Self-citationStriatal and C ortical β‐ A myloidopathy and C ognition in P arkinson's D isease
Shah, N., Frey, K. A., Müller, M. L. T. M., Petrou, M., Kotagal, V., Koeppe, R. A., Scott, P. J. H., Albin, R. L., & Bohnen, N. I. (2015) · Movement Disorders · doi:10.1002/mds.26369 · Cited by 63
Lower cognitive performance in healthy G2019S LRRK2 mutation carriers
Thaler, A., Mirelman, A., Gurevich, T., Simon, E. S., Orr‐Urtreger, A., Marder, K. S., Bressman, S., Giladi, N., Bressman, S., Saunders-Pullman, R. J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182684646 · Cited by 63
Kurz, M. W., Dekomien, G., Nilsen, O. B., Larsen, J. P., Aarsland, D., & Alves, G. W. (2009) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988709332945 · Cited by 62
Self-citationRocha, N. P., Teixeira, A. L., Scalzo, P. L., Barbosa, I. G., de Sousa, M. S., Morato, I. B., Vieira, É. L. M., Christo, P. P., Palotás, A., & Reis, H. J. (2013) · Movement Disorders · doi:10.1002/mds.25752 · Cited by 61
Wu, K., O’Keeffe, D., Politis, M., O’Keeffe, G. C., Robbins, T. W., Bose, S. K., Brooks, D. J., Piccini, P. P., & Barker, R. A. (2012) · Brain · doi:10.1093/brain/aws157 · Cited by 59
Self-citationPlasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease
Lim, N., Swanson, C. R., Cherng, H. R. R., Unger, T. L., Xie, S. X., Weintraub, D. A., MAREK, K. L., Stern, M. B., Siderowf, A. D., PARS Investigators, et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.299 · Cited by 57
Self-citationUnfolded protein response is activated in L ewy body dementias
Baek, J., Whitfield, D., Howlett, D. C., Francis, P. T., Bereczki, E., Ballard, C. G., Hortobágyi, T., Attems, J., & Aarsland, D. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12260 · Cited by 55
Self-citationAlcalay, R. N., Mejia‐Santana, H., Tang, M. X., Rakitin, B. C., Rosado, L., Ross, B., Verbitsky, M., Kisselev, S., Louis, E. D., Comella, C. L., et al. (2010) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390903521018 · Cited by 55
Dopamine receptor mapping with PET imaging in Parkinson’s disease
Niccolini, F., Su, P., & Politis, M. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7302-2 · Cited by 54
Self-citationWinder‐Rhodes, S., Hampshire, A., Rowe, J. B., Peelle, J. E., Robbins, T. W., Owen, A. M., & Barker, R. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.006 · Cited by 54
Ko, W. K. D., Camus, S. M. J., Li, Q., Yang, J., McGuire, S., Pioli, E. Y., & Bézard, E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.012 · Cited by 53
BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease
Białecka, M. A., Kurzawski, M., Roszmann, A., Robowski, P., Sitek, E. J., Honczarenko, K., Mak, M., Deptuła-Jarosz, M., Gołąb-Janowska, M., Droździk, M., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2013.12.051 · Cited by 52
Relationship Between Slowing of the EEG and Cognitive Impairment in Parkinson Disease
Morita, A., Kamei, S., & Mizutani, T. (2011) · Journal of Clinical Neurophysiology · doi:10.1097/wnp.0b013e3182273211 · Cited by 52
Compta, Y., Ibarretxe‐Bilbao, N., Pereira, J. B., Junqué, C., Bargalló, N., TOLOSA, E. S., Valldeoriola, F., Muñoz, E., Cámara, A., Buongiorno, M., et al. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.04.028 · Cited by 52
Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease
Petrou, M., Davatzikos, C. A., Hsieh, M., Foerster, B. R., Albin, R. L., Kotagal, V., Müller, M. L. T. M., Koeppe, R. A., Herman, W. H., Frey, K. A., et al. (2016) · Academic Radiology · doi:10.1016/j.acra.2015.07.014 · Cited by 51
Cognitive dysfunction in Tunisian LRRK2 associated Parkinson’s disease
Sassi, S. B., Nabli, F., Hentati, E., Nahdi, H., Trabelsi, M., Ayed, H. B., Amouri, R., Duda, J. E., Farrer, M. J., & Hentati, F. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.10.009 · Cited by 50
Somme, J. H., Gómez‐Esteban, J. C., Molano, A., Tijero, B., Lezcano, E., & Zarranz, J. J. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.07.047 · Cited by 50
Nie, K., Zhang, Y., Gan, R., Wang, L., Zhao, J., Huang, Z., Tang, H., & Wang, L. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.02.024 · Cited by 49
Cholinergic and perfusion brain networks in Parkinson disease dementia
Colloby, S. J., McKeith, I. G., Burn, D. J., Wyper, D. J., O'Brien, J. T., & Taylor, J. (2016) · Neurology · doi:10.1212/wnl.0000000000002839 · Cited by 49
Skogseth, R. E., Brønnick, K., Pereira, J. B., Mollenhauer, B., Weintraub, D. A., Fladby, T., & Aarsland, D. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150682 · Cited by 46
Self-citationMapping Cortical Atrophy in Parkinson's Disease Patients with Dementia
Hwang, K., Beyer, M. K., Green, A. E., Chung, C., Thompson, P. M., Janvin, C. C., Larsen, J. O., Aarsland, D., & Apostolova, L. G. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-120151 · Cited by 42
Self-citationBrain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson’s disease
Gao, L., Diaz-Corrales, F. J. J., Carrillo, F., Díaz‐Martín, J., Cáceres‐Redondo, M. T., Carballo, M., Palomino, A., López‐Barneo, J., & Mir, P. (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01253.x · Cited by 40
Recent imaging advances in neurology
Rocchi, L., Niccolini, F., & Politis, M. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7711-x · Cited by 40
Self-citationMood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease
Shanker, V., Groves, M., Heiman, G. A., Palmese, C. A., Saunders-Pullman, R. J., Ozelius, L. J., Raymond, D., & Bressman, S. (2011) · Movement Disorders · doi:10.1002/mds.23746 · Cited by 40
Unravelling the nonmotor mysteries of Parkinson disease
Chaudhuri, К. R., & Sauerbier, A. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.236 · Cited by 40
Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?
Yarnall, A. J., Lashley, T., Ling, H., Lees, A. J., Coleman, S. Y., O’Sullivan, S. S., Compta, Y., Révész, T., & Burn, D. J. (2015) · Movement Disorders · doi:10.1002/mds.26422 · Cited by 37
Marquié, M., Locascio, J. J., Rentz, D. M., Becker, J. A., Hedden, T., Johnson, K. A., Growdon, J. H., & Gomperts, S. N. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0052-7 · Cited by 37
Correlation of EEG Slowing with Cognitive Domains in Nondemented Patients with Parkinson's Disease
Zimmermann, R., Gschwandtner, U., Hatz, F., Schindler, C. J. A., Bousleiman, H., Ahmed, S., Hardmeier, M., Meyer, A., Calabrese, P., & Fuhr, P. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000370110 · Cited by 37
Vorovenci, R. J., & Antonini, A. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1113131 · Cited by 33
Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease
Jurado-Coronel, J. C., Ávila-Rodriguez, M., Echeverrı́a, V., Hidalgo‐Lanussa, O., González, J., Aliev, G., & Barreto, G. E. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160202125519 · Cited by 32
Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease
Mengel, D., Dams, J., Ziemek, J., Becker, J., Balzer‐Geldsetzer, M., Hilker, R., Baudrexel, S., Kalbe, E., Schmidt, N., Witt, K., et al. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.04.013 · Cited by 32
Liu, Z., Guo, J., Wang, Y., Li, K., Kang, J.-F., Wei, Y., Sun, Q., Xu, Q., Xu, C., Yan, X., et al. (2016) · Scientific Reports · doi:10.1038/srep19021 · Cited by 31
An Update of the Impact of Deep Brain Stimulation on Non Motor Symptoms in Parkinson's Disease
Klingelhoefer, L., Samuel, M., Chaudhuri, К. R., & Ashkan, K. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-130273 · Cited by 30
Svetel, M. V., Pekmezovic, T. D., Marković, V., Novaković, I. V., Dobričić, V., Djuric, G., Stefanova, E. D., & Kostić, V. (2013) · European Neurology · doi:10.1159/000352033 · Cited by 30
Cited by
Sorted by citations
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
“Moreover there are several candidate genetic risk factors that overlap for AD and PD, most notably APOE and MAPT [127].”
BackgroundHallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States
Mattson, M. P., & Arumugam, T. V. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.011 · Cited by 1,242
Parkinson’s disease: etiopathogenesis and treatment
Jankovic, J. J., & Tan, E. K. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,273
Allocati, N., Masulli, M., Di Ilio, C., & Federici, L. (2018) · Oncogenesis · doi:10.1038/s41389-017-0025-3 · Cited by 625
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
Metadata
- Authors
- Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C.
- Affiliations
- King's College London (GB)
- Corresponding author
- Aarsland, Dag
- Venue
- Nature Reviews Neurology
- Published
- 2017-03-03
- Volume
- 13
- Issue
- 4
- Pages
- 217-231
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC5643027
- OpenAlex
- W2593272776
- Cited by
- 1,027
- References
- 216
- Citations by year
- 2026: 102 · 2025: 99 · 2024: 138 · 2023: 104 · 2022: 105 · 2021: 171 · 2020: 116 · 2019: 89 · 2018: 68 · 2017: 33
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Research Exeter (University of Exeter) (acceptedVersion)
- Figshare (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- South London and Maudsley NHS Foundation Trust
- National Institute for Health and Care Research
- King's College London
- Institute of Psychiatry, Psychology and Neuroscience, King’s College London
- National Institute of Neurological Disorders and Stroke (P50NS053488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Parkinson's disease, cognitive decline, Parkinson's disease dementia, mild cognitive impairment, cerebrospinal fluid biomarkers, amyloid-beta 42, Lewy body pathology, APOE ε4, GBA mutations, cognitive training, nootropic drugs
- MeSH terms
- Dementia, Humans, Parkinson Disease, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
